160
Participants
Start Date
January 26, 2024
Primary Completion Date
September 15, 2025
Study Completion Date
February 1, 2026
Allocetra
Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state
Placebo
The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.
IMSP Institutul de Cardiologie, Chisinau
"Spitalul Clininc Republican T. Mosneaga", Chisinau
"IMSP Sptalul Clinic Municipal Sfanta Treime", Chisinau
Sanos Clinic Herlev, Herlev
Sanos Clinic Syddanmark, Vejle
Sanos Clinic Nordjylland, Gandrup
Hasharon Medical Center, Petah Tikva
Sheba Medical Center, Ramat Gan
Ichilov - Tel Aviv Sourasky Medical Center, Tel Aviv
Rambam Medical Center, Haifa
Kaplan Medical Center, Rehovot
Barzilai Medical Center, Ashkelon
Lead Sponsor
Nordic Bioscience Clinical Development (NBCD)
UNKNOWN
Enlivex Therapeutics Ltd.
INDUSTRY